Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 948 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: acetaminophen Clear all
Completed Not applicable Interventional Results available

Comparing Effectiveness of IV vs Oral Acetaminophen Given Perioperatively for Lap Choles for Pain Control,

NCT01823224
View directory record Official record
Conditions
Laparoscopic Cholecystectomy
Interventions
2 capsules Oral Tylenol 2000 mg and IV "salt water", IV tylenol 1000mg and 2 oral capsule "sugar pills"
Drug
Lead sponsor
Defense and Veterans Center for Integrative Pain Management
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 21, 2026, 12:08 AM EDT
Completed Not applicable Interventional

Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients

NCT03972527
View directory record Official record
Conditions
Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation, Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Head and Neck Cancer
Interventions
Photobiomodulation, Routine Oral Care and Analgesia
Device · Other
Lead sponsor
MuReva Phototherapy Inc.
Industry
Eligibility
22 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Long Beach, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 21, 2026, 12:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?

NCT03541980
View directory record Official record
Conditions
Sickle Cell Anemia Crisis
Interventions
Acetaminophen, Normal saline
Drug
Lead sponsor
Newark Beth Israel Medical Center
Other
Eligibility
4 Years to 16 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Newark, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 21, 2026, 12:08 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Acetaminophen Biomarkers

NCT01005173
View directory record Official record
Conditions
Acetaminophen Toxicity
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
253 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 21, 2026, 12:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

NCT04990388
View directory record Official record
Conditions
Glycogen Storage Disease Type III
Interventions
UX053, Placebo, Antipyretic, H2 Blocker, H1 Blocker
Biological · Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Orange, California • Atlanta, Georgia • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 21, 2026, 12:08 AM EDT
Not listed Phase 2Phase 3 Interventional

Opioid Free Anesthesia vs. Opioid Anesthesia Techniques.

NCT03367988
View directory record Official record
Conditions
Analgesic Drug Dependence, Colectomy
Interventions
Opioid Anesthesia, Opioid-free Anesthesia
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 21, 2026, 12:08 AM EDT
Terminated Phase 4 Interventional Results available

Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage

NCT01530880
View directory record Official record
Conditions
Fever
Interventions
Intravenous Ibuprofen, Acetaminophen (Standard of Care)
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 21, 2026, 12:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ibuprofen and Acetaminophen Versus Ibuprofen and Acetaminophen Plus Hydrocodone for Analgesia After Cesarean Section

NCT03372382
View directory record Official record
Conditions
Opioid Use, Pain, Postoperative
Interventions
Ibuprofen, Acetaminophen, Norco
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 21, 2026, 12:08 AM EDT
Recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
15
States / cities
Phoenix, Arizona • Burbank, California • Grand Junction, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 12:08 AM EDT
Withdrawn Phase 4 Interventional

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Relationship Between Intraoperative Intravenous Acetaminophen and Postoperative Opioid Avoidance for Ambulatory Surgical Procedures

NCT01231191
View directory record Official record
Conditions
Postoperative Pain, Intraoperative and Postoperative Opioid Requirements
Interventions
Intravenous acetaminophen, Intravenous placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 21, 2026, 12:08 AM EDT
Completed Not applicable Interventional Results available

Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy

NCT02111174
View directory record Official record
Conditions
Neuropathy
Interventions
Scrambler Therapy, Sham Therapy
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 21, 2026, 12:08 AM EDT
Recruiting Phase 4 Interventional

Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)

NCT07672015
View directory record Official record
Conditions
Opioid Consumption, Postoperative
Interventions
Suzetrigine, Standard Care (in control arm)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 12:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Determine the Clinical Advantage of IV vs PO Acetaminophen

NCT03558555
View directory record Official record
Conditions
Inguinal Hernia
Interventions
Acetaminophen IV Soln, Oral Acetaminophen, Placebo Pills, Saline
Drug
Lead sponsor
Yan Lai
Other
Eligibility
18 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 21, 2026, 12:08 AM EDT
Completed Phase 3 Interventional Results available

IV Acetaminophen as Adjuvant Analgesic to Hydromorphone - Emergency Department Patients

NCT03553498
View directory record Official record
Conditions
Acute Pain
Interventions
IV acetaminophen, IV placebo, hydromorphone
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 64 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 21, 2026, 12:08 AM EDT
Completed Phase 4 Interventional

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE

NCT06109428
View directory record Official record
Conditions
Analgesia
Interventions
HTX-011, Bupivacaine Hydrochloride, Ibuprofen, Acetaminophen, Luer lock applicator
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Bellaire, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 21, 2026, 12:08 AM EDT
Completed Not applicable Interventional

Accuracy of Needle Placement Into The Subacromial Space of The Shoulder

NCT01330641
View directory record Official record
Conditions
Rotator Cuff Tendonitis
Interventions
Injection of Subacromial Bursa
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced Oct 21, 2026, 12:08 AM EDT
Completed Phase 2 Interventional Results available

Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction

NCT00935311
View directory record Official record
Conditions
Pain
Interventions
ABT-712 Extended-release, Hydrocodone/Acetaminophen Immediate-release, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Austin, Texas • San Marcos, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 21, 2026, 12:08 AM EDT
Completed No phase listed Observational Results available

Tylenol Levels in Bariatric Patients

NCT02982928
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 21, 2026, 12:08 AM EDT
Completed Phase 2 Interventional

Assessing Efficacy of Intravenous Acetaminophen for Perioperative Pain Treatment in Spinal Surgery

NCT05764707
View directory record Official record
Conditions
Lumbar; Injury
Interventions
Acetaminophen, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 21, 2026, 12:08 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache

NCT03472872
View directory record Official record
Conditions
Headache
Interventions
Ketorolac, Acetaminophen
Drug
Lead sponsor
Corewell Health South
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 21, 2026, 12:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control

NCT05477875
View directory record Official record
Conditions
Photorefractive Keratectomy, Myopia, Hyperopia
Interventions
oral cannabinoid, oral codeine/acetaminophen
Drug · Combination Product
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 21, 2026, 12:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects

NCT03517930
View directory record Official record
Conditions
Clinical Pharmacology
Interventions
Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG), Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 21, 2026, 12:08 AM EDT
Completed Phase 3 Interventional

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain.

NCT00315887
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Buprenorphine transdermal delivery system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
22
States / cities
Huntsville, Alabama • Phoenix, Arizona • Waterbury, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated May 3, 2006 · Synced Oct 21, 2026, 12:08 AM EDT
Completed Phase 3 Interventional

Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain

NCT01780428
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Placebo
Drug
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 21, 2026, 12:08 AM EDT